Still betting on Nvidia? Our AI picked this stock instead; it’s up 96%+ THIS MONTH
TORONTO - Quantum BioPharma Ltd. (NASDAQ:QNTM), whose stock has surged over 600% year-to-date according to InvestingPro data, announced Monday it will seek shareholder approval for its previously disclosed non-brokered private placement of class A multiple voting shares at its upcoming annual general meeting on September 26, 2025.
The private placement aims to raise gross proceeds of up to $600, according to the company’s press release. The capital raise comes as InvestingPro data shows the company’s current ratio at 0.78, indicating its short-term obligations exceed liquid assets. Quantum BioPharma expects existing holders of multiple voting shares to subscribe for the entire offering, which is anticipated to close on or about September 26, subject to shareholder approval.
Securities issued through this offering will be subject to a statutory hold period of four months plus one day, in accordance with Canadian securities laws. The company stated it intends to use the proceeds for general working capital purposes.
Quantum BioPharma, which focuses on developing treatments for neurodegenerative and metabolic disorders, filed a material change report regarding the offering more than 21 days before the expected closing date on its SEDAR+ profile.
The company noted that the securities being offered have not been registered under the United States Securities Act of 1933 and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.
Through its subsidiary Lucid Psycheceuticals, Quantum BioPharma is developing Lucid-MS, a patented compound for multiple sclerosis. The company, currently valued at $101.58M market cap, maintains a 20.11% ownership stake in Unbuzzd Wellness Inc. and holds a portfolio of strategic investments through its subsidiary FSD Strategic Investments Inc. Discover more detailed financial metrics and 12 additional exclusive insights about QNTM with InvestingPro.
In other recent news, Quantum BioPharma Ltd. reported strong second-quarter financial results, highlighting an increase in current assets to $10.3 million and the elimination of all debt liabilities. The company’s total assets rose to $15.3 million from $14.9 million in the previous quarter. Additionally, Quantum BioPharma announced a manufacturing agreement through its subsidiary, Huge Biopharma Australia, to produce an oral formulation of Lucid-MS for an upcoming Phase 2 clinical trial. This trial aims to assess the treatment’s efficacy for mobility loss associated with multiple sclerosis. In a joint study with Massachusetts General Hospital, Quantum BioPharma evaluated a PET tracer that showed promise in detecting differences across multiple sclerosis lesions, which are not visible with conventional MRI. Furthermore, the company completed a non-brokered private placement of class A multiple voting shares, raising gross proceeds of up to $600. Quantum BioPharma’s Phase 1 clinical trial for Lucid-MS reported no safety or tolerability concerns, as per the clinical study report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.